Preventing cognitive decline in preclinical Alzheimer's disease

Current Opinion in Pharmacology

Volumn 14, Issue 1, 2014, Pages 18-22

  Riedel, Wim J ^a,b,c  

^a CAMBRIDGE COGNITION   (United Kingdom)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL (TOPIC); COGNITION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PUBLIC-PRIVATE PARTNERSHIP; RISK ASSESSMENT;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; BRAIN; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; COOPERATIVE BEHAVIOR; DEMENTIA; DISEASE PROGRESSION; HUMANS;

EID: 84887857507     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.10.002     Document Type: Review

References (38)

1. A. Wimo, B. Winblad, H. Aguero-Torres, and E. von Strauss The magnitude of dementia occurrence in the world Alzheimer Dis Assoc Disord 17 2003 63 67
2. J.A. Pillai, and J.L. Cummings Clinical trials in predementia stages of Alzheimer disease Med Clin North Am 97 2013 439 457
3. P.T. Nelson, I. Alafuzoff, E.H. Bigio, C. Bouras, H. Braak, N.J. Cairns, R.J. Castellani, B.J. Crain, P. Davies, and K. Del Tredici Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature J Neuropathol Exp Neurol 71 2012 362 381
4. R.C. Petersen, R. Doody, A. Kurz, R.C. Mohs, J.C. Morris, P.V. Rabins, K. Ritchie, M. Rossor, L. Thal, and B. Winblad Current concepts in mild cognitive impairment Arch Neurol 58 2001 1985 1992
5. C.C. Rowe, K.A. Ellis, M. Rimajova, P. Bourgeat, K.E. Pike, G. Jones, J. Fripp, H. Tochon-Danguy, L. Morandeau, and G. O'Keefe Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging Neurobiol Aging 31 2010 1275 1283
6. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, A.M. Fagan, T. Iwatsubo, C.R. Jack Jr., J. Kaye, and T.J. Montine Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
7. G.A. Jicha, E.L. Abner, F.A. Schmitt, R.J. Kryscio, K.P. Riley, G.E. Cooper, N. Stiles, M.S. Mendiondo, C.D. Smith, and L.J. Van Eldik Preclinical AD Workgroup staging: pathological correlates and potential challenges Neurobiol Aging 33 2012 622.e621-622.e616
8. V.L. Villemagne, S. Burnham, P. Bourgeat, B. Brown, K.A. Ellis, O. Salvado, C. Szoeke, S.L. Macaulay, R. Martins, and P. Maruff Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study Lancet Neurol 12 2013 357 367
9. C.R. Jack Jr., D.S. Knopman, S.D. Weigand, H.J. Wiste, P. Vemuri, V. Lowe, K. Kantarci, J.L. Gunter, M.L. Senjem, and R.J. Ivnik An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease Ann Neurol 71 2012 765 775
10. S.J. Vos, C. Xiong, P.J. Visser, M.S. Jasielec, J. Hassenstab, E.A. Grant, N.J. Cairns, J.C. Morris, D.M. Holtzman, and A.M. Fagan Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study Lancet Neurol 12 2013 957 965 10.1016/S1474-4422(13)70194-7 Available online 4 September 2013, ISSN 1474-4422
11. B. Dubois, H.H. Feldman, C. Jacova, J.L. Cummings, S.T. Dekosky, P. Barberger-Gateau, A. Delacourte, G. Frisoni, N.C. Fox, and D. Galasko Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 9 2010 1118 1127
12. D.S. Knopman, C.R. Jack Jr., H.J. Wiste, S.D. Weigand, P. Vemuri, V. Lowe, K. Kantarci, J.L. Gunter, M.L. Senjem, and R.J. Ivnik Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease Neurology 78 2012 1576 1582
13. Center for Drug Evaluation and Research (CDER) Guidance for Industry: Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease 2013 Dept. of Health and Human Services, Food and Drug Administration Washington, DC
14. N. Kozauer, and R. Katz Regulatory innovation and drug development for early-stage Alzheimer's disease N Engl J Med 368 2013 1169 1171
15. M.S. Albert, M.B. Moss, R. Tanzi, and K. Jones Preclinical prediction of AD using neuropsychological tests J Int Neuropsychol Soc 7 2001 631 639
16. M. Storandt, M.A. Mintun, D. Head, and J.C. Morris Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition Arch Neurol 66 2009 1476 1481
17. R.C. Mohs, D. Knopman, R.C. Petersen, S.H. Ferris, C. Ernesto, M. Grundman, M. Sano, L. Bieliauskas, D. Geldmacher, and C. Clark Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study Alzheimer Dis Assoc Disord 11 1997 S13 S21
18. J. Harrison, S.L. Minassian, L. Jenkins, R.S. Black, M. Koller, and M. Grundman A neuropsychological test battery for use in Alzheimer disease clinical trials Arch Neurol 64 2007 1323 1329
19. J.M. Cedarbaum, M. Jaros, C. Hernandez, N. Coley, S. Andrieu, M. Grundman, and B. Vellas Alzheimer's Disease Neuroimaging I: rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials Alzheimers Dement 9 2013 S45 S55
20. T. Hedden, H. Oh, A.P. Younger, and T.A. Patel Meta-analysis of amyloid-cognition relations in cognitively normal older adults Neurology 80 2013 1341 1348
21. K.A. Ellis, Y.Y. Lim, K. Harrington, D. Ames, A.I. Bush, D. Darby, R.N. Martins, C.L. Masters, C.C. Rowe, and G. Savage Decline in cognitive function over 18 months in healthy older adults with high amyloid-beta J Alzheimers Dis 34 2013 861 871
22. Y.Y. Lim, R.H. Pietrzak, K.A. Ellis, J. Jaeger, K. Harrington, T. Ashwood, C. Szoeke, R.N. Martins, A.I. Bush, and C.L. Masters Rapid decline in episodic memory in healthy older adults with high amyloid-beta J Alzheimers Dis 33 2013 675 679
23. V.L. Villemagne, K.E. Pike, G. Chetelat, K.A. Ellis, R.S. Mulligan, P. Bourgeat, U. Ackermann, G. Jones, C. Szoeke, and O. Salvado Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease Ann Neurol 69 2011 181 192
24. Y.Y. Lim, K.A. Ellis, R.H. Pietrzak, D. Ames, D. Darby, K. Harrington, R.N. Martins, C.L. Masters, C. Rowe, and G. Savage Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults Neurology 79 2012 1645 1652
25. J. Junkkila, S. Oja, M. Laine, and M. Karrasch Applicability of the CANTAB-PAL computerized memory test in identifying amnestic mild cognitive impairment and Alzheimer's disease Dement Geriatr Cogn Disord 34 2012 83 89
26. A. Hampshire, R.R. Highfield, B.L. Parkin, and A.M. Owen Fractionating human intelligence Neuron 76 2012 1225 1237
27. F.W. Sabb, G. Hellemann, D. Lau, J.R. Vanderlan, H.J. Cohen, R.M. Bilder, and J.T. McCracken High-throughput cognitive assessment using BrainTest.org: examining cognitive control in a family cohort Brain Behav 2013 10.1002/brb3.158
28. J. Brandt, C. Sullivan, L.E. Burrell 2nd, M. Rogerson, and A. Anderson Internet-based screening for dementia risk PLoS ONE 8 2013 e57476
29. National Audit Office Improving Services and Support for People with Dementia 2007 Edited by Office TS London Available at: http://www.nao.org.uk
30. D. Getsios, S. Blume, K.J. Ishak, G. Maclaine, and L. Hernandez An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom Alzheimers Dement 8 2012 22 30
31. M.W. Weiner, D.P. Veitch, P.S. Aisen, L.A. Beckett, N.J. Cairns, R.C. Green, D. Harvey, C.R. Jack, W. Jagust, and E. Liu The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement 9 2013 e111 e194
32. K.A. Ellis, A.I. Bush, D. Darby, D. De Fazio, J. Foster, P. Hudson, N.T. Lautenschlager, N. Lenzo, R.N. Martins, and P. Maruff The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease Int Psychogeriatr 21 2009 672 687
33. P.J. Visser, F.R. Verhey, M. Boada, R. Bullock, P.P. De Deyn, G.B. Frisoni, L. Frolich, H. Hampel, J. Jolles, and R. Jones Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA Study Neuroepidemiology 30 2008 254 265
34. D.J. Selkoe Preventing Alzheimer's disease Science 337 2012 1488 1492
35. M. Macaluso, M. Krams, and S.H. Preskorn Phase I trials: from traditional to newer approaches part II J Psychiatr Pract 17 2011 277 284
36. M. Macaluso, M. Krams, and S.H. Preskorn Phase I trials: from traditional to newer approaches. Part I J Psychiatr Pract 17 2011 200 203
37. A.D. Barker, C.C. Sigman, G.J. Kelloff, N.M. Hylton, D.A. Berry, and L.J. Esserman I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy Clin Pharmacol Ther 86 2009 97 100
38. R.A. Sperling, M. Krams, M. Poole, S. Lovestone, R.A. Stern, and M.T. Ropacki Building an adaptive trial in AD: challenges and solutions L.J. Bain, Prevention of Alzheimer's Disease - What Will It Take? 2013 The New York Academy of Sciences Academy eBriefings http://www.nyas.org/publications/EBriefings/ Detail.aspx?cid=2050c5d7-008b-4064-ab85-4c0a2be9ba52# (accessed 8.10.13)